ClinicalTrials.gg
CompletedNCT04751539Updated May 11, 2021

A Dose-escalation Study of AND017 in Healthy Subjects

A Phase 1 interventional study of AND017 single dose and AND017 multiple dose in Healthy Volunteers, sponsored by Kind Pharmaceuticals LLC. Completed at 1 site in Australia. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by Kind Pharmaceuticals LLC · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Jul 2018, registered Jan 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a phase I, randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate safety, tolerability, PKs and PDs of AND017 following oral single and multiple dose administration.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Kind Pharmaceuticals LLC is the lead sponsor of 11 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. within 18.0-30.0 kg/m2 (inclusive)
  2. Blood Pressure (BP) and 12-lead (ECG) showing no abnormalities during screening;
  3. No clinically significant abnormal values in physical examination, clinical laboratory tests, liver function or kidney function;

Exclusion criteria

Exclusion Criteria:

  1. Current or chronic history of liver disease or known hepatic or biliary abnormalities, including but not limited to , alkaline phosphatase and >1.5xULN (isolated bilirubin>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%);
  2. Subjects with : male \<120 g/L or >160 g/L, female \<110 g/L or >150 g/L;
  3. Subjects with any abnormalities of hematology during screening: Mean corpuscular volume (MCV), count, serum iron, ferritin;
  4. Subjects with a history of medical treatment or disease likely to increase the risk of bleeding or disturbance of blood coagulation;
  5. History of deep vein thrombosis, stoke, , pulmonary embolism or other thrombosis-related condition within the last five years;
  6. History of myocardial infarction, heart failure or acute coronary syndrome;
  7. Evidence of active peptic, duodenal or esophageal ulcer disease at screening;
  8. History of pulmonary artery hypertension;
  9. History of sensitivity to heparin or heparin-induced thrombocytopenia;
  10. Subjects with major illness or surgery within past 3 months prior to screening, or planned surgery during study;
  11. Known or suspected history of drug abuse within the past 5 years or presence of drug abuse within 3 months before study;
  12. Donated blood >400 mL or significant blood loss equivalent to 400 mL or received blood transfusion within 3months of screening; or donated blood >200 mL or significant blood loss equivalent to 200 mL within 1 month prior to screening.
  13. Participation in any clinical study with an drug, biologic or device within 4 weeks or 5 times the half-life of the specific drug/biologics (whichever is longer), prior to dosing;
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    AND017 single dose escalation

    Subjects will be administrated with single dose of AND017 capsule from 1 mg to 50 mg during Part A.

    Drug: AND017 single dose

  • Placebo comparator
    AND017 repeated dose escalation

    Subjects will be administrated with repeated dose of AND017 from 4 mg to 30 mg for 10 consecutive days during Part B.

    Drug: AND017 multiple dose

  • Placebo comparator
    Placebo

    Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B

    Drug: Placebo

Interventions

  • AND017 administrated as oral single-dose on Day 1 in Part A

  • DrugAND017 multiple dose

    AND017 administrated once daily from Day 1 to Day 10 in Part B

  • DrugPlacebo

    Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B

06

What researchers measure

Primary outcomes

  1. Safety evaluations

    Incidents of AE and abnormal laboratory tests

    Time frame: 17 Days

Secondary outcomes

  1. Plasma Cmax of AND017

    The plasma Cmax of AND017 by single dose administration

    Time frame: 1 day

  2. Plasma Tmax of AND017

    The plasma Tmax of AND017 after single dose administration on D1 and multiple doses for 10 consecutive days on D10

    Time frame: 1 day and 10 days

  3. Plasma t1/2 of AND017

    The plasma T1/2 of AND017 after single dose administration on D1 and multiple doses for 10 consecutive days on D10

    Time frame: 1 day and 10 days

  4. Plasma AUC of AND017

    The plasma AUCs of AND017 after single dose administration on D1 and multiple doses for 10 consecutive days on D10

    Time frame: 1 day and 10 days

  5. Plasma CL/F of AND017

    The plasma CL/F of AND017 after single dose administration

    Time frame: 1 day

  6. Plasma Vz/F of AND017

    The plasma Vz/F of AND017 after single dose administration

    Time frame: 1 day

  7. Plasma MRT of AND017

    The plasma MRT of AND017 after single dose administration

    Time frame: 1 day

  8. Plasma λz of AND017

    The plasma λz of AND017 after single dose administration

    Time frame: 1 day

  9. Plasma %AUCex of AND017

    The plasma %AUCex of AND017 after single dose administration

    Time frame: 1 day

  10. Plasma Css,min of AND017

    The plasma Css,min of AND017 by multiple administration for 10 consecutive days

    Time frame: 10 days

  11. Plasma Css,max of AND017

    The plasma Css,max of AND017 by multiple administration for 10 consecutive days

    Time frame: 10 days

  12. Plasma Css,avg of AND017

    The plasma Css,avg of AND017 by multiple administration for 10 consecutive days

    Time frame: 10 days

  13. Plasma CLss/F of AND017

    The plasma CLss/F of AND017 by multiple administration for 10 consecutive days

    Time frame: 10 days

  14. Plasma Vss/F of AND017

    The plasma Vss/F of AND017 by multiple administration for 10 consecutive days

    Time frame: 10 days

  15. Plasma Rac(AUC) of AND017

    The plasma Rac(AUC) of AND017 by multiple administration for 10 consecutive days

    Time frame: 10 days

  16. Plasma DF of AND017

    The plasma DF of AND017 by multiple administration for 10 consecutive days

    Time frame: 10 days

  17. PD parameters

    Change from baseline levels of EPO

    Time frame: 17 days

  18. PD parameters

    Change from baseline levels of HB

    Time frame: 17 days

  19. PD parameters

    Change from baseline levels of RET

    Time frame: 17 days

07

Study locations

1 site
  • Scientia Clinical Research
    Randwick, New South Wales 2031, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Feb 2019, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2021
First posted
Feb 12, 2021
StartActual
Jul 16, 2018
Primary completionActual
Feb 11, 2019
CompletionActual
Feb 11, 2019
Last update
May 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04751539
Lead sponsor
Kind Pharmaceuticals LLC
Responsible party
Sponsor
First posted
Feb 12, 2021
Start date
Jul 16, 2018
Primary completion
Feb 11, 2019
Completion
Feb 11, 2019
Last update
May 11, 2021

Study contacts

Yusha Zhu, MD PhD
study director · Kind Pharmaceuticals LLC

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AND017

Start the discussion